Loading stock data…
$153.19+1.32 (+0.87%)
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
Belite Bio, Inc in the Healthcare sector is trading at $153.19 with a market capitalization of $7.8B. Wall Street consensus targets $228.89 (9 analysts), implying a +49.4% move over the next 12 months. The stock is currently 23% below its 52-week high of $200.00, remaining 4.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.91M↓ | -$32.68M↓ | -$28.08M↓ | -$23.02M↓ | -$17.60M |
| Net Income | -$28.41M↓ | -$26.94M↓ | -$25.32M↓ | -$21.69M↓ | -$16.32M |
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally ...